jRCT ロゴ

臨床研究等提出・公開システム

Top

Japanese

Mar. 30, 2019

Jan. 26, 2024

jRCTs051180229

ALS biomarker research using patient clinical samples

ALS biomarker research

Inoue Haruhisa

Kyoto University

53 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan

+81-75-366-7360

prj-als_bosutinib@cira.kyoto-u.ac.jp

Inoue Haruhisa

Kyoto University

53 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan

+81-75-366-7360

prj-als_bosutinib@cira.kyoto-u.ac.jp

Recruiting

Mar. 31, 2019

April. 19, 2019
49

Interventional

non-randomized controlled trial

open(masking not used)

historical control

parallel assignment

basic science

Those who agree to attend the current clinical study among ALS patients joining an accompanying clinical trial "Phase 1/2 Dose Escalation Study of Bostinib in Patients with Amyotrophic Lateral Sclerosis (ALS)"

N/A

20age old over
75age old under

Both

amyotrophic lateral sclerosis (ALS)

collection of cerebrospinal fluid

ALS

Alteration of blood biomerkers including SOD1, TDP-43, Src, c-Abl, etc.
Alteration of CSF biomerkers including neurofilament L, phosphorylated neurofilament H, SOD1, TDP-43, etc.
Alteration of urine biomerkers including p75, etc.
Plasma concentration of bosutinib (through value)
CSF concentration of bosutinib (through value)
Evaluation of biomerkers using iPS cells

N/A

Japan Agency for Medical Research and Development
Not applicable
Kyoto University Certified Review Board
Yoshida-Konoe-cho, Sakyo-ku, Kyoto 606-8501, JAPAN, Kyoto

+81-75-753-4680

ethcom@kuhp.kyoto-u.ac.jp
Approval

Mar. 04, 2019

No

none

History of Changes

No Publication date
11 Jan. 26, 2024 (this page) Changes
10 April. 26, 2023 Detail Changes
9 Nov. 29, 2022 Detail Changes
8 Oct. 19, 2022 Detail Changes
7 Mar. 30, 2022 Detail Changes
6 June. 09, 2021 Detail Changes
5 Feb. 08, 2021 Detail Changes
4 Aug. 06, 2019 Detail Changes
3 July. 22, 2019 Detail Changes
2 April. 22, 2019 Detail Changes
1 Mar. 30, 2019 Detail